The Christie NHS Foundation Trust

Two major clinical trials presented at ASTRO 2025 reached opposite conclusions about proton beam therapy's effectiveness compared to intensity-modulated radiotherapy (IMRT) for head and neck cancer treatment.

Poolbeg Pharma has secured Accelerating Clinical Trials Limited to conduct the POLB 001 Phase 2a trial and obtained free supply of an approved bispecific antibody drug for the study.

DEP-SN38, a dendrimer nanoparticle formulation of topoisomerase I inhibitor SN38, demonstrated encouraging anticancer activity in 114 heavily pretreated patients with advanced solid tumors including ovarian, colorectal, pancreatic, and breast cancers.

The groundbreaking LION trial investigates the combination of celecoxib with immunotherapy to treat advanced triple-negative breast cancer, non-small cell lung cancer, and renal cell carcinoma.

The TOURIST trial, the world's largest of its kind, is recruiting nearly 1,000 patients with stage IV non-small cell lung cancer (NSCLC) to assess the benefits of radiotherapy.

Mike Peters, frontman of The Alarm, achieved remission from aggressive Richter's syndrome after participating in an NHS drug trial at The Christie in Manchester.

The NHS Cancer Vaccine Launch Pad program will provide personalised mRNA vaccines to thousands of cancer patients across 30 hospitals in England to prevent disease recurrence.